Pharmacopeia Targets 2009 For SARM Phase II After Gaining Program From Bristol
Company licenses the Phase I selective androgen receptor modulator for muscle wasting from Bristol in exchange for research support.
Company licenses the Phase I selective androgen receptor modulator for muscle wasting from Bristol in exchange for research support.